Basal insulin analogues in the management of diabetes mellitus: What progress have we made? - Wikidata - awgldk - TriplyDB

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

http://www.wikidata.org/entity/Q38136581

about

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials Concepts and clinical use of ultra-long basal insulin Modern basal insulin analogs: An incomplete story Update on the treatment of type 2 diabetes mellitus rDNA insulin glargine U300 - a critical appraisal Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.Personalized pharmacotherapy in diabetes care using clinical pharmacology data of basal insulin analogues.New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?Glycemic variability and acute ischemic stroke: the missing link?Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?U300, a novel long-acting insulin formulation.The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.Pursuit of a perfect insulin.Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response.The clinical potential of low-level C-peptide secretion.How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes.Glargine and degludec: Solution behaviour of higher dose synthetic insulins.LAPS Insulin115: A novel ultra-long-acting basal insulin with a unique action profile.Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes.Advances in Basal Insulin Therapy.

P2860

Q26767164-14E16038-67F0-4A9A-919C-4A62DBBD38AD Q26770354-4C4D729D-851C-4013-A9ED-1D315435DE2E Q27015047-63A94C27-AA8C-49F0-BCE8-FB380D29D08B Q28073342-2BED220D-B7FD-46F8-82C3-9008D007EAB1 Q28077366-C52F4698-945C-425B-8AF9-0B9F991A7906 Q30248803-EDE18B75-A689-4472-9489-FF8B86416983 Q30809002-4B26D919-448C-413C-8961-9708D95CD476 Q37343841-263537EB-9BF8-4610-A0D8-AFFE6A4BD4B6 Q37394470-7D7CD82F-AC14-49C6-80A6-34747100746D Q37732207-D701E730-E6E1-42EB-8CD3-149527158192 Q37737467-B8CAF4B1-8692-4F2D-827B-BACCDEE010A3 Q38170326-DFC19630-9BED-40D6-AAA0-D5B5C1F220AD Q38176677-0C3FC73D-ACBC-4D27-9DED-F0C810C15BE7 Q38199712-2D599D47-3A07-4CBE-8213-ABED3D3A5CF5 Q38236166-AEB88D7D-87D8-47B5-BA94-586402038136 Q38239532-36D02B6A-3C5A-484D-BDB9-0222EA93079E Q38259756-2309B58F-E7E4-44C9-9684-F6765FB6B528 Q38628035-61769218-67F8-40A2-AD97-DFBE8A506083 Q38715053-B47F6382-C069-4646-9814-B8AE44A9DDC6 Q38778988-097B66EC-FBDF-4425-8C3C-CB17ED4D824D Q38807485-7ADA8EFC-F37A-43BC-B4EE-313E1C266E5D Q38889362-FEC35A9A-C385-4FD7-8B6F-F8A4894701E1 Q39023191-BA9E1D34-6D78-4329-874F-665EF7872EB0 Q41260941-D276595D-025F-4F51-8372-C1C9DCAB1737 Q42509647-F3BF6961-5E50-4463-A007-FFE2F2666FA5 Q53448284-D9B8A3BF-3A2D-4B03-B5EF-392F1AA820C6 Q55309585-F86867EC-69DA-42DC-8783-4AAD351DDFDC

P2860

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

http://www.wikidata.org/entity/Q38136581

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Basal insulin analogues in the ...... s: What progress have we made?

@en

type

label

Basal insulin analogues in the ...... s: What progress have we made?

@en

prefLabel

Basal insulin analogues in the ...... s: What progress have we made?

@en

P1433

Q38136581-81CC5681-DBAC-48AD-923A-0A8C525B62B1

P1476

Q38136581-09F63D2C-7F85-4B7F-BC13-870B965E7022

P2093

Q38136581-4E153B1B-E11B-4109-B709-3553AEAEDF2B

Q38136581-8A03C70A-4521-4106-B3AB-B29B9B737E60

Q38136581-CA9438EC-9553-437E-9741-259A38F162A4

P2860

Q38136581-01679F15-D8F5-4E24-A77F-0149864AFF36

Q38136581-0A3AC0D2-2423-45FF-A8A3-34FC024C5379

Q38136581-0D4103A1-AD46-4C66-BAC9-EBDA7B2A2D9A

Q38136581-0E6EBE57-72AC-426C-9B13-0CCB555C3064

Q38136581-0F8B4819-42F3-45CF-BE5D-0CB48DF48D40

Q38136581-122302B7-E205-4FB1-9A58-F759A25E9635

Q38136581-1265AE2A-77D3-40FB-9DAE-A32BE6A8BB1F

Q38136581-15BBDAD5-99D6-4BBB-AEA9-552300F6672B

Q38136581-1AA6C743-8BAD-484A-AFB1-0D4BBBD763E5

Q38136581-1D9D76CB-64A2-41AD-B34A-312CF1E22223

P304

Q38136581-E6F65661-22DC-401F-9925-F5A555469A4E

P31

Q38136581-268E8D27-5768-4432-AB44-0D2124BABF0F

P356

Q38136581-CA783AFD-506F-4CF7-8681-F3213BBDD855

P433

Q38136581-77085AE0-0DC6-414D-96E9-67CBF2D8B54D

P478

Q38136581-22A55B85-7299-4927-97B2-0794D22F5D34

P577

Q38136581-D4C9026D-A106-4293-B659-91A9863FE2A6

P698

Q38136581-2FDF06C8-8E50-4CCD-81AD-9BE3071673BC

P921

Q38136581-48F8068A-AE26-4AD3-85F3-A6AFA847A48C

P356

P1433

Diabetes - Metabolism: Research and Reviews

P1476

Basal insulin analogues in the ...... s: What progress have we made?

@en

P2093

David R Owens

http://www.w3.org/2001/XMLSchema#string

Glenn Matfin

http://www.w3.org/2001/XMLSchema#string

Louis Monnier

http://www.w3.org/2001/XMLSchema#string

P2860

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

Expression in Escherichia coli of chemically synthesized genes for human insulin

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.

Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.

P304

104-119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DMRR.2469

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24026961

http://www.w3.org/2001/XMLSchema#string

P921